The biotech ecosystem's trusted infrastructure for capital raising, licensing partnerships and grant discovery. Verified connections. Structured data. Real deals.
Pre-IND data, IP status and deal terms. Nothing opens by default.
Both parties sign before anything opens. Full company detail, documents and terms live inside the deal room, not in your inbox. Access is granted, never assumed.
Three tiers: email (auto), LinkedIn (manual), company registration (admin-approved). Know who you are talking to.
Automated detection blocks phone numbers, personal emails and LinkedIn URLs in messages. Keep sensitive conversations on-platform.
There is always a free tier. Paid plans lower your success fee and are never required. Biochart earns when your deal does.
Tell Biochart what you are building and onboarding adapts to it. Your modality, your stage, your next milestone. You get something useful before you ever speak to an investor.
Your modality, your template. Six development templates, each with its own phases and durations, not a generic project plan.
A next action, not a blank page. The platform tells you what moves the raise forward this week, based on where your program actually is.
Goals against reality. Set target dates, then watch variance as the program moves. On course, behind or at risk, tracked automatically.
Each template carries its own phases and durations, editable as the program moves.
From profile to partnership in three steps.
Build a structured profile with the data that matters. Founders add development timelines. Investors specify investment thesis. BD&L teams outline partnership criteria.
Ranked by therapeutic area, stage, geography and deal type. Save searches to get alerts when new opportunities appear.
Both parties sign before anything opens. Once signed, the deal room is granted and secure messaging begins.
Most platforms stop at the introduction. That is the easy part. Biochart runs everything after it: diligence, documents and terms, in one room per relationship, with a record of who saw what.
Both parties submit terms without seeing the other. Nothing is revealed until both are in, and once revealed the numbers lock against quiet edits.
Access is granted at room level and logged. No forwarding, no shared links, no orphaned attachments.
Nineteen document types, every version kept, with a view log showing who opened what and when.
Each party sees their own success fee, calculated on the deal currency. Nothing hidden, nothing to reconcile.
No waiting months for the next industry event. Connect with the right people today.
Structured CDAs gate the deal room before conversations start. No manual paperwork.
Structured profiles with Gantt charts, IP status and regulatory pathways. No digging through 50-slide decks.
Tiered verification ensures you are talking to real decision-makers, not tire-kickers.
Illustrative program view. Variance is tracked against goal dates.
Nothing opens until both parties sign a CDA and a deal room is granted. Access is per room, and every document view is logged.
Free to join and free to use. Paid plans lower your success fee and are never required. You pay nothing until a deal closes.
A first cohort in 2027. Waitlist members get in first and help decide what ships.
Small molecule, biologic, cell therapy, RNA therapy, ADC and peptide, each with its own development template.
Biochart opens to a first cohort in 2027. Join the waitlist and help shape what ships.